Business · 06/01/2015
FDA Clears Path for Atazanavir Sulfate 100mg Capsules
The US Food and Drug Administration (FDA) has made a determination that REYATAZ (atazanavir sulfate) 100mg capsules were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications (ANDAs) for this medication.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →